Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284309 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 321
- Enrollment target
NCT01284309: Completed Phase 1 study, sponsored by Astellas Pharma.
NCT01284309 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 321 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (435% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284309, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.
Primary Outcome
Day 56 data will include subjects who discontinue early due to elevated IOP
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
What the finished NCT01284309 record still lists
NCT01284309 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (435% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01284309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01284309 about?
NCT01284309 is a clinical study titled "A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects". The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.
What is the current status of trial NCT01284309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 321 participants. The study started on 2010-11. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01284309?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT01284309?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01284309's enrollment target sits among peer trials
321 111th of 2000 higher than 1,889 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia